Health and Fitness Health and Fitness
Wed, November 30, 2011
[ Wed, Nov 30th 2011 ] - Market Wire
Cytokinetics Announces Positive Results From Phas .. g CK-2017357 in Patients With Amyotrophic Lateral
[ Wed, Nov 30th 2011 ] - Market Wire
United States Patent and Trademark Office Upholds .. Patents in Two Re-Examination Cases Brought by Is
[ Wed, Nov 30th 2011 ] - Market Wire
Capital Senior Living Corporation to Present at O .. thcare Conference on Wednesday, December 14, 2011
[ Wed, Nov 30th 2011 ] - Market Wire
Compugen Presents Predictive Drug Target Discovery Platform at European Antibody Conference
[ Wed, Nov 30th 2011 ] - Market Wire
Curis Announces Agreement with The Leukemia & Lym .. evelop CUDC-907 for Lymphoma and Multiple Myeloma
[ Wed, Nov 30th 2011 ] - Market Wire
Given Imaging Files Patent Infringement Lawsuit in Korea Against Intromedic
[ Wed, Nov 30th 2011 ] - Market Wire
FONAR Sells UPRIGHT Multi-Position MRI Scanner to .. hased Dynamic Weight-Bearing Multi-Position MRI T
[ Wed, Nov 30th 2011 ] - Market Wire
Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
[ Wed, Nov 30th 2011 ] - Market Wire
Soliris (culizumab) obtient une autorisation de m .. ur le traitement des patients atteints du syndrom
[ Wed, Nov 30th 2011 ] - Market Wire
Positive Clinical Study Results Reported by Adeona's Oral Zinc for ALS Collaborator
[ Wed, Nov 30th 2011 ] - Market Wire
Astex Pharmaceuticals to Present at World Epigenetics Summit on December 8th
[ Wed, Nov 30th 2011 ] - Market Wire
Watson Launches Generic LIPITOR
Tue, November 29, 2011
[ Tue, Nov 29th 2011 ] - Market Wire
Gilead ottiene dagli enti normativi europei compe .. ommercializzazione di Eviplera, un nuovo regime c
[ Tue, Nov 29th 2011 ] - Market Wire
Clovis Oncology Announces Exercise of Underwriter .. se 700,000 Shares of Clovis Oncology Common Stock
[ Tue, Nov 29th 2011 ] - Market Wire
Elan Provides an Update on ELND005 (Scyllo-inositol)
[ Tue, Nov 29th 2011 ] - Market Wire
St. Jude Medical Announces FDA Approval of Industryas First Quadripolar Pacing System
[ Tue, Nov 29th 2011 ] - Market Wire
NPS Pharmaceuticals to Present at Deutsche Bank BioFEST Conference
[ Tue, Nov 29th 2011 ] - Market Wire
Health Management Associates, Inc. to Present at .. a Merrill Lynch 2011 Leveraged Finance Conference
[ Tue, Nov 29th 2011 ] - Market Wire
BioMarin Initiates Phase 2 Study for GALNS in Patients Under Five Years of Age With MPS IVA
[ Tue, Nov 29th 2011 ] - Market Wire
Ceapro Reports Third Quarter 2011 Financial Results
[ Tue, Nov 29th 2011 ] - Market Wire
Senesco Technologies, Inc. to Webcast, Live, at RetailInvestorConferences.com on December 1st
[ Tue, Nov 29th 2011 ] - Market Wire
Natural Alternatives International, Inc. Announce .. Beta-Alanine Patent Protecting CarnoSyn Products
[ Tue, Nov 29th 2011 ] - Market Wire
Soliris (eculizumab) riceve l'autorizzazione alla .. a per il trattamento dei pazienti affetti da sind
[ Tue, Nov 29th 2011 ] - Market Wire
NeuroMetrix to Present at Canaccord Genuity 6th A .. ular, Aesthetics & Metabolic Disorders Conference
[ Tue, Nov 29th 2011 ] - Market Wire
Extraordinary general meeting of shareholders of Basilea Pharmaceutica Ltd.
[ Tue, Nov 29th 2011 ] - Market Wire
TheraBiogen, Inc. Launches National Radio Ad Campaign
[ Tue, Nov 29th 2011 ] - Market Wire
Medicure Reports First Quarter 2012 Financial Results
[ Tue, Nov 29th 2011 ] - Market Wire
Gilead krijgt Europese vergunning voor het in de .. een nieuw, compleet eenmaal daags enkel-tablet r
[ Tue, Nov 29th 2011 ] - Market Wire
Vergunning verleend voor het in de handel brengen .. Europa ter behandeling van patinten met atypisch
[ Tue, Nov 29th 2011 ] - Market Wire
Soliris (eculizumab) obtiene autorizacin para com .. l tratamiento de pacientes con sndrome urmico hem

Soliris (eculizumab) obtiene autorizacin para comercializacin en Europa para el tratamiento de pacientes con sndrome urmico hem


Published on 2011-11-29 08:45:56 - Market Wire
  Print publication without navigation


CHESHIRE, Conn.--([ ])--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) ha anunciado que la Comisin Europea (CE) ha ampliado la indicacin teraputica de Soliris (eculizumab) para incluir el tratamiento de pacientes peditricos y adultos con sndrome urmico hemoltico atpico (aHUS). Soliris es el primer tratamiento aprobado en la Unin Europea para aHUS, una enfermedad gentica, crnica, potencialmente letal y muy rara que daa progresivamente rganos vitales, produciendo apopleja, ataques al corazn, fallo renal y la muerte1.

El comunicado en el idioma original, es la versin oficial y autorizada del mismo. La traduccin es solamente un medio de ayuda y deber ser comparada con el texto en idioma original, que es la nica versin del texto que tendr validez legal.

Contributing Sources